for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

U.S. appeals court revives GlaxoSmithKline verdict against Teva

Oct 2 (Reuters) - A federal appeals court on Friday reinstated a 2017 jury verdict that required Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than $235 million for infringing a patent for its blood pressure drug Coreg.

The 2-1 decision was issued by the U.S. Federal Circuit Court of Appeals in Washington, D.C. (Reporting by Jonathan Stempel in New York Editing by Chizu Nomiyama)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up